Advances in diagnostic tools have dramatically expanded in the past year, making available to patients several blood tests to help diagnose Alzheimer’s disease. Dr. Joel Braunstein, Chief Executive Officer of C2N Diagnostics, helped bring the first Alzheimer’s blood test to market with support from the ADDF. Now, C2N is developing a platform that will enable global access to its next generation PrectivityAD2™ blood test and other precision medicine tools. These tests enable healthcare providers to give patients an early and accurate diagnosis.
“Tomorrow’s Breakthroughs Today” features world-class scientists discussing the path toward new, cutting-edge treatments for Alzheimer’s disease. Now in its fifth season, this lecture series invites three top investigators to share the latest breaking updates on their research with moderator Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to rapidly accelerating the development of novel therapeutics and biomarkers to prevent, treat, and cure Alzheimer’s disease and related dementias.
Presented by the Alzheimer’s Drug Discovery Foundation in partnership with Heidi and Tom McWilliams
